ZYUS Life Sciences Corporation Stock price

Equities

ZYUS

CA9899601095

Biotechnology & Medical Research

Delayed Toronto S.E. 03:56:03 2024-03-27 pm EDT 5-day change 1st Jan Change
1.02 CAD -2.86% Intraday chart for ZYUS Life Sciences Corporation -1.92% +13.33%
Sales 2023 * 382K 282K Sales 2024 * 479K 354K Capitalization 72.26M 53.36M
Net income 2023 * - Net income 2024 * - EV / Sales 2023 * 189 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 151 x
P/E ratio 2023 *
-
P/E ratio 2024 *
-
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 42.01%
More Fundamentals * Assessed data
Dynamic Chart
Calian Group and MDA Brief: Calian Says "Strengthens Nuclear Capability" with Acquisition of MDA Ltd. Nuclear Assets MT
Calian Group Says Won Contract to Support Clinical Trial for ZYUS Life Sciences' Lead Drug Product Candidate MT
Calian Group Brief: Says Won Contract to Support Clinical Trial for ZYUS Life Sciences' Lead Drug Product Candidate MT
ZYUS Life Sciences Appoints Dr. Hance Clarke to Clinical Advisory Committee MT
Zyus Appoints Dr. Hance Clarke as Clinical Advisory Committee CI
ZYUS Life Sciences Corp. Announces Phase 2 Trial Evaluating Trichomylin Softgel Capsules for Advanced Cancer Pain Care MT
ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin®? Softgel Capsules for Advanced Cancer Pain Management CI
ZYUS Life Sciences Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
ZYUS Life Sciences Corp. Brief: Announced "Positive" Phase I Clinical Trial Results for Trichomylin Softgels MT
ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin® Softgels CI
ZYUS Life Sciences Corporation Appoints Tim Miller as Director of Investor Relations and Capital Markets, Effective November 1, 2023 CI
ZYUS Life Sciences Corporation Obtains Health Canada Security Clearance for New Board Member, Wayne Brownlee and Announces Reconstitution of its Board Committees CI
ZYUS Life Sciences Initiated at Speculative Buy at Stifel GMP; Price Target Set at C$4.00 MT
ZYUS Life Sciences Corporation Strengthens Board of Directors with the Appointment of Wayne Brownlee CI
ZYUS Life Sciences Corporation Auditor Raises 'Going Concern' Doubt CI
More news
1 day-2.86%
1 week-1.92%
1 month+4.08%
3 months+15.91%
6 months+0.99%
Current year+13.33%
More quotes
1 week
1.01
Extreme 1.01
1.05
1 month
0.98
Extreme 0.98
1.12
Current year
0.84
Extreme 0.84
1.12
1 year
0.71
Extreme 0.71
1.41
3 years
0.71
Extreme 0.71
1.41
5 years
0.71
Extreme 0.71
1.41
10 years
0.71
Extreme 0.71
1.41
More quotes
Managers TitleAgeSince
Founder 61 18-03-31
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 71 23-06-28
Director/Board Member 68 20-08-31
Founder 61 18-03-31
More insiders
Date Price Change Volume
24-03-27 1.02 -2.86% 8,295
24-03-26 1.05 +0.96% 100
24-03-25 1.04 -1.89% 800
24-03-21 1.06 +1.92% 300
24-03-20 1.04 -2.80% 4,400

Delayed Quote Toronto S.E., March 27, 2024 at 03:56 pm EDT

More quotes
ZYUS Life Sciences Corporation is a Canada-based life sciences company. The Company is focused on the global development and commercialization of cannabinoid-based pharmaceutical drug product candidates and exempt market therapeutics. Through clinical research, it is committed to furthering the understanding of cannabinoids with the clinical development of its pharmaceutical drug product candidates and intellectual property activities to protect its novel formulations. Additionally, the Company delivers cGMP / EU GMP-compliant cannabinoid products to patients through the exempt global medical market. The Company is also focused on commercialization of its exempt market therapeutics, such as cannabinoid oils, soft gel capsules and topical creams, in Canada and those international markets where medical cannabis is legal.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.02 CAD
Average target price
2.75 CAD
Spread / Average Target
+169.61%
Consensus
  1. Stock
  2. Equities
  3. Stock ZYUS Life Sciences Corporation - Toronto S.E.